• 1
    PDQ®, National Cancer Institute, Washington, D.C., 2000.
  • 2
    Burris H, Storniola AM. Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouricil. Eur J Can 1997;33: S1822.
  • 3
    Burris III HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15: 240313.
  • 4
    Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Semin Oncol 1997;24: S7-24–28.
  • 5
    McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J Natl Cancer Inst 1996;88: 1193203.
  • 6
    Shewach DS, Hahn TM, Chang E, et al. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994;54: 321823.
  • 7
    Lawrence TS, Chang EY, Hahn TM, et al. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 1996;34: 86772.
  • 8
    Heinemann V, Hertel LW, Grindey GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-d-arabinofuranosylcytosine. Cancer Res 1988;48: 402431.
  • 9
    Shewach DS, Reynolds KK, Hertel L. Nucleotide specificity of human deoxycytidine kinase. Mol Pharmacol 1992;42: 51824.
  • 10
    Baker CH, Banzor J, Bollinger JM, et al. 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 1991;34: 187984.
  • 11
    Huang P, Chubb S, Hertel LW, et al. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51: 61107.
  • 12
    Schy WE, Hertel LW, Kroin JS, et al. Effect of a template-located 2′,2′-difluorodeoxycytidine on the kinetics and fidelity on base insertion by Klemow (3′-5′ exonuclease) fragment. Cancer Res 1994;54: 321823.
  • 13
    Talamonti MS, Catalano PJ, Vaughn DJ, et al. Eastern cooperative oncology group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 2000;18: 33849.
  • 14
    Gold DV, Lew K., Maliniak R, et al. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int J Cancer 1994; 57: 20410.
  • 15
    Gold DV, Alisauskas R, Sharkey RM. Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4. Cancer Res 1995;55: 110510.
  • 16
    Alisauskus R, Wong GYC, Gold DV. Initial studies of monoclonal antibody PAM4 targeting to xenografted orthotopic pancreatic cancer. Cancer Res 1995;55: 5743s8s.
  • 17
    Mariani G, Molea N, Bacciardi D, et al. Initial tumor targeting, biodistribution and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer. Cancer Res 1995;55: 5911s5s.
  • 18
    Leung S-O, Goldenberg DM, Dion AS, et al. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol Immunol 1995;32: 141327.
  • 19
    McConahey PJ, Dixon FJ. A method of trace iodination of proteins for immunological studies. Int Arch Allergy Immunol 1966;29: 18592.
  • 20
    Theilen GH, Madewell B. Veterinary cancer medicine. Philadelphia: Lea and Feiger, 1987. 189.
  • 21
    Blumenthal RD, Sharkey RM, Kashi R, et al. Comparison of therapeutic efficacy and host toxicity of 2 different I-131-labeled antibodies and their fragments in the GW-39 colonic cancer xenograft model. Int J Cancer 1989;44: 292300.
  • 22
    Goldenberg DM. Imaging and therapy of gastrointestinal cancers with radiolabeled antibodies. Am J Gast 1991;86: 1392403.
  • 23
    Goldenberg DM. New developments in monoclonal antibodies for cancer detection and therapy. CA Cancer J Clin 1994;44: 4364.
  • 24
    Juweid ME, Hajjar G, Stein R, et al. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. J Nucl Med 2000;41: 93103.
  • 25
    Behr TM, Salib AL, Liersch T, et al. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a Phase I clinical study. Clin Cancer Res 1999;5: 3232s42s.
  • 26
    Behr TM, Wormann B, Gramatzki M, et al. Low- vs. high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin Cancer Res 1999;5: 3304s14s.
  • 27
    O'Donnell RT, DeNardo GL, Kukis DL, et al. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin lymphoma. J Nucl Med 1999;40: 201420.
  • 28
    O'Donnell RT, DeNardo GL, Kukis DL, et al. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl]-TETA-Lym-1 for radioimmunotherapy on non-Hodgkin lymphoma. Clin Cancer Res 1999;5: 3330s6s.
  • 29
    Wiseman GA, White CA, Witzig TE, et al. Radioimmunotherapy of relapsed non-Hodgkin lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 1999;5: 3281s6s.
  • 30
    Lawrence TS, Chang EY, Hahn TM, et al. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (gemcitabine). Clin Cancer Res 1997;3: 77782.
  • 31
    Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999;59: 10714.
  • 32
    Robertson JM, Shewach DS, Lawrence TS. Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma. Cancer 1996;78: 6749.
  • 33
    Bagshaw MA, Doggett RLS, Smith KC, et al. Intraarterial 5-bromodeoxyuridine and X-ray therapy. Am J Roentgenol Radium Ther Nucl Med 1967;99: 88694.
  • 34
    Mason KA, Milas L, Hunter NR, et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 1999;44: 112535.
  • 35
    Brennan MF, Kinsella T, Friedman M. Cancer of the pancreas. In: DeVitaVT, HellmanS, RosenbergSA, eds. Cancer principles and practice of oncology, 3rd ed. Philadelphia: Lippincott, 1989. 80035.
  • 36
    Dobelbouer RR, Howards JM, Bagne FR, et al. Treatment of cancer of the pancreas by precision high dose external photon beam and intraoperative electron beam therapy. Int J Radiat Oncol Biol Phys 1989;16: 2059.
  • 37
    Zerbi A, Fossati V, Parolini D, et al. Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer. Cancer 1994;73: 29305.
  • 38
    Okamoto A, Tsuruta K, Isawa T, et al. Intraoperative radiation therapy for pancreatic carcinoma. Int J Pancreatol 1994;16: 15764.
  • 39
    Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987;59: 200610.
  • 40
    Coia L, Hoffman J, Scher R, et al. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Cancer 1994;73: 106775.
  • 41
    Gold DV, Cardillo T, Vardi Y, et al. Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4. Int J Cancer 1997;71: 6607.